| Dr Enrique Yambao Galura, MD | |
|
14100 58th St N, Clearwater, FL 33760-9900 | |
| (727) 824-8181 | |
| Not Available |
| Full Name | Dr Enrique Yambao Galura |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 14100 58th St N, Clearwater, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134332034 | NPI | - | NPPES |
| ME 37402 | Other | FL | STATE MEDICAL BOARD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | ME 37402 (Florida) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | ME27402 (Florida) | Primary |
| Entity Name | Florida Clinical Practice Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063463768 PECOS PAC ID: 0345146254 Enrollment ID: O20031211000099 |
News Archive
As the COVID-19 pandemic continues to spread, and research related to potential risk factors for COVID-19 mortality continues, it is becoming clear that individuals with underlying comorbidities have a greater risk of death from COVID-19. The exact contribution of different comorbidities is unclear, however. Now, a new study published in the journal PLOS ONE dissects this topic and may help to quantify the risk posed by specific conditions and offer help with the prognosis.
Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.
A study conducted by Sarah Farabi, PhD, RN, while she was a post-doctoral fellow working with Dr. Teri Hernandez at the University of Colorado College of Nursing and School of Medicine in 2018 found that mild sleep apnea changed sugar levels during pregnancy and was connected to infant growth patterns related to increased risk of obesity.
Older people who take omega-3 fish oil supplements are probably not reducing their chances of losing cognitive function, according to a new Cochrane systematic review.
› Verified 8 days ago
| Entity Name | Tallahassee Memorial Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437177664 PECOS PAC ID: 6103724778 Enrollment ID: O20031222000279 |
News Archive
As the COVID-19 pandemic continues to spread, and research related to potential risk factors for COVID-19 mortality continues, it is becoming clear that individuals with underlying comorbidities have a greater risk of death from COVID-19. The exact contribution of different comorbidities is unclear, however. Now, a new study published in the journal PLOS ONE dissects this topic and may help to quantify the risk posed by specific conditions and offer help with the prognosis.
Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.
A study conducted by Sarah Farabi, PhD, RN, while she was a post-doctoral fellow working with Dr. Teri Hernandez at the University of Colorado College of Nursing and School of Medicine in 2018 found that mild sleep apnea changed sugar levels during pregnancy and was connected to infant growth patterns related to increased risk of obesity.
Older people who take omega-3 fish oil supplements are probably not reducing their chances of losing cognitive function, according to a new Cochrane systematic review.
› Verified 8 days ago
| Entity Name | Community Health Center Of Pinellas Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467873315 PECOS PAC ID: 8527961028 Enrollment ID: O20040131000031 |
News Archive
As the COVID-19 pandemic continues to spread, and research related to potential risk factors for COVID-19 mortality continues, it is becoming clear that individuals with underlying comorbidities have a greater risk of death from COVID-19. The exact contribution of different comorbidities is unclear, however. Now, a new study published in the journal PLOS ONE dissects this topic and may help to quantify the risk posed by specific conditions and offer help with the prognosis.
Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.
A study conducted by Sarah Farabi, PhD, RN, while she was a post-doctoral fellow working with Dr. Teri Hernandez at the University of Colorado College of Nursing and School of Medicine in 2018 found that mild sleep apnea changed sugar levels during pregnancy and was connected to infant growth patterns related to increased risk of obesity.
Older people who take omega-3 fish oil supplements are probably not reducing their chances of losing cognitive function, according to a new Cochrane systematic review.
› Verified 8 days ago
| Entity Name | Metropolitan Charities Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013277060 PECOS PAC ID: 2163668286 Enrollment ID: O20130416000529 |
News Archive
As the COVID-19 pandemic continues to spread, and research related to potential risk factors for COVID-19 mortality continues, it is becoming clear that individuals with underlying comorbidities have a greater risk of death from COVID-19. The exact contribution of different comorbidities is unclear, however. Now, a new study published in the journal PLOS ONE dissects this topic and may help to quantify the risk posed by specific conditions and offer help with the prognosis.
Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.
A study conducted by Sarah Farabi, PhD, RN, while she was a post-doctoral fellow working with Dr. Teri Hernandez at the University of Colorado College of Nursing and School of Medicine in 2018 found that mild sleep apnea changed sugar levels during pregnancy and was connected to infant growth patterns related to increased risk of obesity.
Older people who take omega-3 fish oil supplements are probably not reducing their chances of losing cognitive function, according to a new Cochrane systematic review.
› Verified 8 days ago
| Entity Name | Hni Medical Services Of Florida, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679048284 PECOS PAC ID: 7517202112 Enrollment ID: O20190102000426 |
News Archive
As the COVID-19 pandemic continues to spread, and research related to potential risk factors for COVID-19 mortality continues, it is becoming clear that individuals with underlying comorbidities have a greater risk of death from COVID-19. The exact contribution of different comorbidities is unclear, however. Now, a new study published in the journal PLOS ONE dissects this topic and may help to quantify the risk posed by specific conditions and offer help with the prognosis.
Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.
A study conducted by Sarah Farabi, PhD, RN, while she was a post-doctoral fellow working with Dr. Teri Hernandez at the University of Colorado College of Nursing and School of Medicine in 2018 found that mild sleep apnea changed sugar levels during pregnancy and was connected to infant growth patterns related to increased risk of obesity.
Older people who take omega-3 fish oil supplements are probably not reducing their chances of losing cognitive function, according to a new Cochrane systematic review.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Enrique Yambao Galura, MD 14100 58th St N, Clearwater, FL 33760-9900 Ph: (727) 824-8181 | Dr Enrique Yambao Galura, MD 14100 58th St N, Clearwater, FL 33760-9900 Ph: (727) 824-8181 |
News Archive
As the COVID-19 pandemic continues to spread, and research related to potential risk factors for COVID-19 mortality continues, it is becoming clear that individuals with underlying comorbidities have a greater risk of death from COVID-19. The exact contribution of different comorbidities is unclear, however. Now, a new study published in the journal PLOS ONE dissects this topic and may help to quantify the risk posed by specific conditions and offer help with the prognosis.
Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.
A study conducted by Sarah Farabi, PhD, RN, while she was a post-doctoral fellow working with Dr. Teri Hernandez at the University of Colorado College of Nursing and School of Medicine in 2018 found that mild sleep apnea changed sugar levels during pregnancy and was connected to infant growth patterns related to increased risk of obesity.
Older people who take omega-3 fish oil supplements are probably not reducing their chances of losing cognitive function, according to a new Cochrane systematic review.
› Verified 8 days ago
Kiran Rabheru, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 300 Pinellas St, Clearwater, FL 33756 Phone: 727-298-6283 Fax: 727-462-7650 | |
Dr. William Michael Hervey, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1437 S Belcher Rd, Clearwater, FL 33764 Phone: 727-524-4464 Fax: 727-210-6945 | |
Nicole Angermeier, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 11300 Us Highway 19 N, Clearwater, FL 33764 Phone: 330-379-5083 | |
Dr. Carl Tyler Shenkman, M.D., J.D., LLM Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 501 S Lincoln Ave Ste 22, Clearwater, FL 33756 Phone: 727-357-7828 Fax: 727-337-7646 | |
Dr. Luis G Figueroa, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2250 Drew St, Clearwater, FL 33765 Phone: 727-797-7463 Fax: 727-216-0374 | |
Dr. Maykel Luna Concepcion, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 300 Pinellas St, Clearwater, FL 33756 Phone: 727-532-1355 Fax: 727-266-4928 | |
Dr. Michelle Scargle, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2454 N Mcmullen Booth Rd Ste 502, 503, Clearwater, FL 33759 Phone: 727-285-8770 Fax: 727-285-8770 |